CLRB Cellectar Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1279704 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-37.2%
TTM EPS YoY70.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-170.0%
ROA-116.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets24.6%
Debt / equity0.00x
Current ratio4.44x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $5.44M | $4.56M | $3.01M | $3.16M | $2.52M | $2.39M | $3.43M | $6.21M |
| SG&A expense | $2.67M | $2.64M | $2.79M | $2.53M | $2.33M | $3.65M | $2.97M | $6.54M |
| Operating income | -$8.10M | -$7.20M | -$5.79M | -$5.69M | -$4.85M | -$6.04M | -$6.40M | -$12.74M |
| Net income | -$7.97M | -$6.93M | -$5.65M | -$5.30M | -$4.44M | -$5.45M | -$6.60M | -$2.36M |
| EBITDA | — | — | — | -$5.64M | -$4.80M | -$5.98M | -$6.34M | -$12.68M |
| EPS (basic) | -0.46 | -0.57 | -1.33 | — | -1.41 | -3.39 | -4.30 | — |
| EPS (diluted) | -0.46 | -0.57 | -1.33 | — | -1.41 | -3.39 | -4.30 | — |
| Weighted avg. shares (diluted) | 17.46M | 12.23M | 4.24M | — | 3.16M | 1.61M | 1.54M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $24.58M | $33.99M | $8.35M | $13.20M | $12.55M | $11.04M | $13.91M | $23.29M |
| Current assets | $25.71M | $34.88M | $9.27M | $14.04M | $13.62M | $12.62M | $14.89M | $24.25M |
| PP&E, net | $268,905 | $304,173 | $339,697 | $549,405 | $595,271 | $647,549 | $700,826 | $757,121 |
| Total assets | $29.74M | $36.64M | $11.12M | $14.98M | $14.63M | $13.70M | $16.04M | $25.47M |
| Current liabilities | $5.80M | $5.24M | $4.87M | $4.75M | $4.91M | $5.87M | $6.02M | $9.39M |
| Total liabilities | $7.33M | $6.77M | $6.40M | $5.06M | $5.25M | $6.23M | $6.41M | $9.80M |
| Shareholders' equity | $22.42M | $29.87M | $3.34M | $8.54M | $8.00M | $6.09M | $8.25M | $14.29M |
| Shares outstanding | 10.04M | 8.25M | 4.24M | 4.24M | 3.19M | 1.81M | 46.08M | 1.54M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.41M | -$6.01M | -$4.85M | -$4.34M | -$4.28M | -$5.12M | -$9.38M | -$10.91M |
| Capital expenditure | $0 | $0 | $3,378 | — | — | — | — | $61,286 |
| Free cash flow | -$9.41M | -$6.01M | -$4.85M | — | — | — | — | -$10.97M |
| Investing cash flow | $0 | $0 | -$3,378 | — | — | — | — | -$61,286 |
| Financing cash flow | $5 | — | — | $4.99M | $5.79M | — | — | $0 |
| Depreciation & amortization | — | — | — | $49,461 | $52,277 | $55,564 | $56,295 | $68,571 |
| Stock-based compensation | $518,273 | $428,306 | $451,869 | $567,788 | $567,788 | $565,391 | $562,737 | $1.49M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.